Hasil Pencarian  ::  Simpan CSV :: Kembali

"Designed to support the development of new, effective therapeutics, Topical and transdermal drug delivery : principles and practice explains the principles underlying the field and then demonstrates how these principles are put into practice in the design and development of new drug products. Drawing together and reviewing the latest research findings, the book focuses on practical, tested, and proven approaches that are backed by industry case studies and the authors' firsthand experience. Moreover, the book emphasizes the mechanistic information that is essential for successful drug product development."

"The volume ?Appetite control? provides a comprehensive description of the mechanisms controlling food intake, and thereby energy balance, in the mammalian organism. During the last decade, research in this area has produced a remarkable wealth of information and has characterized the function of numerous peptides, transmitters, and receptors in appetite control. Dysfunction of these circuits leads to obesity, a growing health concern. However, the plethora of mechanistic information is in marked contrasts to an almost complete lack of anti-obesity drugs that meet the safety standards required for the chronic therapy of morbid obesity. Consequently, ongoing research aims to identify additional targets and agents for a pharmacological intervention. Thus, the mechanisms of appetite control as well as all agents interfering with its control are of considerable practical interest."

"Kanker serviks menempati urutan keempat untuk jenis kanker yang sering menyerang wanita dengan estimasi 570,000 kasus pada 2018 di mana merepresentasikan 6,6% dari kanker pada wanita dan di Indonesia terdapat 32,469 kasus kanker serviks. Salah satu teknologi yang sedang dikembangkan untuk terapi kanker adalah teknologi pengantaran obat dengan nanopartikel sebagai agen pembawa dari obat anti kanker. Nanopartikel Fe3O4 merupakan salah satu nanopartikel yang dapat diaplikasikan dalam teknologi penghantaran obat dikarenakan sifat magnetik dan juga toksisitasnya yang rendah. Konjugasi asam folat pada nanopartikel juga menjadi salah satu teknologi untuk meningkatkan sifat penargetan dalam penghantaran obat doxorubicin pada sel kanker dikarenakan tingginya afinitas ikatan antara asam folat dengan reseptor folat, senyawa yang terekpresi pada sel kanker. Pada penelitian ini, dilakukan konjugasi doxorubicin dan asam folat pada nanopartikel Fe3O4 terstabilisasi asam aspartat (FA-AA-MNPs) dengan memvariasikan jumlah asam aspartat untuk melihat stabilitas koloid nanokomposit, efisiensi loading release obat doxorubicin yang terkonjugasi, dan melihat pengaruh konjugasi asam folat terhadap uji viabilitas sel. Uji viabilitas sel akan dilakukan menggunakan sel HeLa dengan menggunakan MTT Assays. Fluorescence imaging dilakukan untuk melihat interaksi dan lokasi doxorubicin pada sel HeLa. Dari hasil studi drug loading yang dilakukan, setiap nanokomposit memiliki kemampuan mengikat doxorubicin sebesar 70% pada rasio doxorubicin dan nanokomposit adalah 2:1. Pada uji drug release dengan metode dialisis, nanokomposit FA-32mmolAA-MNPs memiliki kemampuan melepas 68 % doroxubicin sedangkan nanokomposit lainnya hanya melepas 36% doxorubicin. Kemampuan nanokomposit dalam terapi kanker serviks tertarget diuji dengan MTT assays. Nanokomposit terkonjugasi asam folat cenderung memiliki nilai viabilitas sel lebih rendah dibandingkan nanokomposit tanpa asam folat dan DOX-FA-32mmolAA adalah nanokomposit dengan nilai viabilitas sel paling rendah yaitu 78%. Cervical cancer is the fourth most frequent cancer in women with an estimated 570,000 new cases in 2018 representing 6.6% of all female cancers and there are 32.469 cases of cervical cancer in Indonesia. One of technology that is being developed for cancer therapy is using nanoparticle as drug carrier in drug delivery technology. Fe3O4 nanoparticles is one of the nanoparticles that can be applied in drug delivery technology due to its magnetic properties and low toxicity. Conjugation of folic acid in nanoparticles has also become one of the technologies to improve the targeting nature of doxorubicin in cancer cells due to the high affinity of bonds between folic acid and folic receptors, compounds that are over-expressed in cancer cells. In this study, folic acid and doxorubicin are conjugated to Fe3O4 nanoparticles stabilized by aspartic acid (FA-AA-MNPs) with varying amount of aspartic acid to see the stability of the colloidal nanocomposite, the efficiency of loading and release of doxorubicin, and see the effect of folic acid as ligand targeting. Cell viability test will be carried out using HeLa cells using MTT assays. Fluorescence imaging was conducted to see the interaction and the location of doxorubicin in HeLa cells. The results of drug loading studies exhibit if each nanocomposite has the ability to bind 70% doxorubicin at the ratio of doxorubicin and nanocomposite is 2: 1. In drug release assays by dialysis method, FA-32mmolAA-MNPs have the ability to release 68% doxorubicin besides the other nanocomposite only release 36% doxorubicin. The ability of nanocomposites in targeted cervical cancer therapy in vitro was tested by MTT assays. Nanocomposites with folic acid showed lower percentage of viability cells than nanocomposite without folic acid and DOX-FA-32mmolAA-MNPs had the lowest percentage viability cells that is 78%."

"Pengobatan epilepsi melalui rute oral seringkali tidak efektif, karena obat-obat tersebut menghadapi tantangan metabolisme lintas pertama, degradasi enzim, dan penetrasi yang rendah ke dalam otak akibat adanya sawar darah otak. Masalah tersebut dapat diatasi melalui pengembangan sistem intranasal yang dibantu dengan liposom. Tujuan penelitian ini melakukan formulasi liposom asam valproat sebagai obat epilepsi untuk meningkatkan bioavailabilitas di otak melalui rute intranasal. Liposom asam valproat dibuat dengan teknik hidrasi lapis tipis menggunakan fosfatidilkolin kedelai dan kolesterol. Selanjutnya dikarakterisasi berdasarkan ukuran, indeks poli dispersitas (IPD), potensial zeta, morfologi obat, persentase kadar obat, dan pelepasan obat ex vivo. Formulasi liposom juga diuji stabilitasnya pada suhu berbeda. Uji in vivo dilakukan pada tikus albino Wistar untuk menentukan profil farmakokinetik dan biodistribusi obat. Sampel uji masing-masing diberikan secara oral, intraperitoneal (IP) pada tikus (n=5) dengan menganalisis perbandingan kadar asam valproat pada plasma dengan otak. Hasil karakterisasi fisik terbaik adalah pada formula 4 pada ukuran partikel, IPD, potensial zeta, dan efisiensi penjerapan pada formulasi teroptimasi berturut-turut adalah 92,01±1,87 nm, 0,21±0,01, -46,33±6,47 mV, dan 82,19±4,72%. Hasil uji TEM dengan perbesaran 40.000x menunjukkan bahwa liposom asam valproat memiliki bentuk molekul bulat (sferis) dan ukuran partikel di bawah 250 nm. Hasil uji stabilitas menunjukkan bahwa formulasi tidak mengalami perubahan ketika disimpan pada suhu 4±2 °C dan 25±2 °C selama enam bulan. Hasil uji ex vivo menggunakan lapisan mukosa hidung domba menunjukkan liposom dapat meningkatkan penetrasi asam valproat sebesar 200,24 ± 5.25 µg.cm-2.jam-1. Berdasarkan uji in vivo, nilai konsentrasi asam valproat yang dienkapsulasi dengan liposom yang diberikan dengan rute intranasal meningkat dibandingkan dengan kelompok asam valproat non liposom, intraperitoneal dan oral. Uji biodistribusi menunjukkan liposom asam valproat berhasil meningkatkan efisiensi penargetan obat di otak dibandingkan plasma sebesar 1,15 kali. Hasil yang diperoleh menunjukkan keberhasilan formulasi liposom asam valproat yang sesuai untuk rute intranasal dengan potensi penargetan otak.

---

The treatment of epilepsy via oral route often faces challenges such as first-pass metabolism, enzymatic degradation, and low brain penetration due to the blood-brain barrier. These issues can be addressed through the development of intranasal systems assisted by liposomes. The aim of this study was to formulate liposomes containing valproic acid as an epilepsy drug to enhance brain bioavailability through intranasal administration. Liposomes containing valproic acid were prepared using the thin-film hydration technique with soy phosphatidylcholine and cholesterol. Subsequently, they were characterized based on size, polydispersity index (PDI), zeta potential, drug morphology, drug content percentage, and ex vivo drug release. The stability of the liposome formulation was also tested at different temperatures. In vivo testing was conducted on Wistar albino rats to determine the pharmacokinetic profile and drug biodistribution. Samples were administered orally and intraperitoneally (IP) to the rats (n=5), analyzing the comparison of valproic acid levels in plasma and the brain. The best physical characterization results were obtained from formula 4 with particle size, PDI, zeta potential, and encapsulation efficiency in the optimized formulation being 92.01±1.87 nm, 0.21±0.01, -46.33±6.47 mV, and 82.19±4.72%, respectively. Transmission electron microscopy (TEM) analysis at a magnification of 40,000x showed that valproic acid-loaded liposomes had spherical molecular shapes and particle sizes below 250 nm. Stability testing indicated that the formulation remained unchanged when stored at 4±2 °C and 25±2 °C for six months. Ex vivo testing using sheep nasal mucosa demonstrated that the liposomes increased valproic acid penetration by 200.24 ± 5.25 µg.cm-2.hour-1. Based on in vivo testing, the concentration of valproic acid encapsulated in liposomes administered intranasally increased compared to non-liposomal valproic acid, intraperitoneal, and oral groups. Biodistribution testing indicated that valproic acid-loaded liposomes successfully enhanced drug targeting efficiency in the brain compared to plasma by 1.15 times. The results obtained indicate the successful formulation of valproic acid-loaded liposomes suitable for intranasal administration with potential brain targeting capability."

"This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease."

"Compatibility of pharmaceutical products and contact materials helps pharmaceutical, toxicology, analytical, and regulatory affairs professionals assess the safety of leachable and extractable chemicals associated with drug product packaging, manufacturing systems, and devices. The most comprehensive resource available, its coverage includes the strategies, tactics, and regulatory requirements for performing safety assessments, along with the means for interpreting results.Structured around a logical framework for an extractables and leachables safety assessment and closely linked to the pharmaceutical product development process, Compatibility of Pharmaceutical Products and Contact Materials directly addresses the fundamental questions of "what activities need to be performed to completely, efficiently, and effectively address the issue of product safety from an extractables and leachables perspective?" and "when do the various required activities need to be performed?" Specifically, the chapters describe :- Pertinent regulations and practical ways to meet guidelines- Coordinating manufacturing, storage, and delivery systems development and qualification with therapeutic product development- Materials characterization and the materials screening process- Component and/or system qualification (illustrated by several case studies)- Performing validation/migration studies and interpreting and reporting the results- Creating a product registration dossier and putting it through regulatory review- Product maintenance (Change Control) from an extractables and leachables perspective- Likely future developments in extractables and leachables assessmentAdditionally, the book's appendix provides a database, including CAS registry numbers, chemical formulas and molecular weights of extractable/leachable substances that have been reported in the chemical literature."

"This book gives an updated and expert overview of nuclear hormone receptors in drug metabolism and drug development and equips you with the interdisciplinary understanding of these receptors and how they can be regulated. Pharmaceutical researchers will find this extremely useful in developing drugs for cancer, heart disease, and diabetes treatment. This comprehensive resource collects scattered materials into one handy, informative volume."

"This comprehensive resource covers the fundamentals, formulation, and biopharmaceutical issues of lipid-based drug delivery. It presents the principles of lipid absorption and covers formulation issues, such as dissolution testing and stability testing, and physiological and biopharmaceutical issues, including the role of specific enzymes, the evaluation of transport systems in the body, and the mechanisms governing the transport of water-insoluble drugs."